Drug
Nerandomilast (JASCAYD®)
Status:
To Patients
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Detail
Nerandomilast (JASCAYD®) is an investigational, oral, phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects.
Study Purpose
Nerandomilast (JASCAYD®) has received FDA approval. The drug is currently undergoing evaluation in additional clinical trials.